Is Erasca Inc (ERAS) overvalued? · $4.13B cap
Erasca Inc (ERAS) is a biotechnology company listed on US.
This page asks whether Erasca Inc (ERAS) looks expensive on cached numbers — not a short thesis.
No cached income statement for ERAS, so there is no earnings base to call rich or cheap.
ERAS currently screens at market cap $4.13B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ERAS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ERAS stock page for the full model, not this heading.
Not investment advice.